Remove 2020 Remove Pharmaceutical Companies Remove Pharmaceutical Manufacturing
article thumbnail

Understanding the Regulatory Environment in Japan for Generic Drug Development

Drug Patent Watch

This article aims to provide a comprehensive overview of the key aspects of the regulatory framework, highlighting the requirements and challenges faced by pharmaceutical companies seeking to introduce generic drugs into the Japanese market. Retrieved from [link] Japan Pharmaceutical Manufacturers Association.

article thumbnail

Addressing US FDA challenges in Indian sterile drug manufacturing – Part 1

Express Pharma

Indian pharmaceutical companies supply more than 60 per cent of global demand for vaccines and over 40 per cent of generic medicines consumed in the United States (2). For instance, India’s role as a major supplier of COVID-19 vaccines underscored its capabilities in high-volume sterile manufacturing (4). and EU markets.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024

Pharmaceutical Technology

Both modalities have emerged as the most used platform technologies in developing oligonucleotide-based drugs for CNS disorders since 2020. ASOs accounted for more than half ($3.54 billion), while siRNAs made up more than a third ($2.51 billion) of these deals.

article thumbnail

Who’s saying what? Environmental sustainability mentions in company filings of pharmaceutical industry increased by 114% in Q1 2023

Pharmaceutical Technology

The global pharmaceutical industry experienced a 114% rise in company filings mentions of environmental sustainability in Q1 2023 compared with the previous quarter, with the highest share accounted for by Novozymes with 27% year-on-year increase, according to GlobalData’s analysis of over 757 pharmaceutical company filings.

article thumbnail

Who’s saying what? Corporate governance mentions in company filings of pharmaceutical industry increased by 141% in Q1 2023

Pharmaceutical Technology

The global pharmaceutical industry experienced a 141% rise in company filings mentions of corporate governance in Q1 2023 compared with the previous quarter, with the highest share accounted for by GSK with 306% year-on-year increase, according to GlobalData’s analysis of over 898 pharmaceutical company filings.

article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR). Other reasons include lower sales demand and high investment costs.

article thumbnail

Who’s saying what? Corporate governance mentions in company filings of pharmaceutical industry increased by 141% in Q1 2023

Pharmaceutical Technology

The global pharmaceutical industry experienced a 141% rise in company filings mentions of corporate governance in Q1 2023 compared with the previous quarter, with the highest share accounted for by GSK with 306% year-on-year increase, according to GlobalData’s analysis of over 898 pharmaceutical company filings.